TY - JOUR
T1 - The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes
T2 - Results from the kidney early evaluation program (KEEP)
AU - Amin, Amit P.
AU - Whaley-Connell, Adam T.
AU - Li, Suying
AU - Chen, Shu Cheng
AU - McCullough, Peter A.
AU - Kosiborod, Mikhail N.
N1 - Funding Information:
Support: KEEP is a program of the National Kidney Foundation Inc and is supported by Abbott, Amgen, LifeScan, Siemens, Genentech, GM Foundation, Nephroceuticals, and Pfizer. Dr Amin is supported by grant KM1CA156708 , National Cancer Institute, National Institutes of Health (NIH), and grants UL1 TR000448 , KL2 TR000450 , and TL1 TR000449 , Clinical and Translational Science Award, National Center for Advancing Translational Sciences (NCATS) , NIH. Manuscript contents are solely the responsibility of the authors and do not necessarily represent the official view of NCATS or NIH. Dr Whaley-Connell is supported by the Department of Veterans Affairs Career Development Award-2, NIH grant R03AG040638 , and the American Society of Nephrology-Association of Specialty Professors Development Grant in Geriatric Nephrology. Dr Kosiborod is supported by research grants from the American Heart Association , Medtronic Diabetes , Glumetrics , and Gilead .
PY - 2013/4
Y1 - 2013/4
N2 - Introduction: Chronic kidney disease may complicate diabetes, often manifesting with reduced glomerular filtration rate (GFR), albuminuria, or both. Although greater albuminuria and lower estimated GFR both predict adverse prognosis, whether a synergistic prognostic interaction occurs in patients with diabetes has not been defined in a large national cohort study. Methods: We used 2000-2011 data from the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) for 42,761 participants with diabetes. Kaplan-Meier survival analysis and multivariable Cox regression were used to ascertain the association of estimated GFR, albumin-creatinine ratio (ACR), and their interaction on all-cause mortality and progression to end-stage renal disease (ESRD) at a median 4 years of follow-up. Results: Of 42,761 participants with diabetes, 8,618 (20.2%) had estimated GFR <60 mL/min/1.73 m2, 7,715 (18.0%) had ACR >30 mg/g, and 2,641 (6.2%) had both. The unadjusted incidence (per 1,000 person-years) of all-cause mortality increased from 3.1 (95% CI, 2.4-3.8) in participants with estimated GFR ≥105 mL/min/1.73 m2 and no albuminuria to 73.7 (95% CI, 54.9-92.5) in participants with estimated GFR <30 mL/min/1.73 m2 and macroalbuminuria (P < 0.001). Progression to ESRD likewise increased from 0.2 (95% CI, 0-0.4) to 220.4 (95% CI, 177.2-263.6) per 1,000 person-years (P < 0.001). After adjustment for confounders, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction (P for interaction < 0.001); estimated GFR <30 mL/min/1.73 m2 and macroalbuminuria together were associated with a 5-fold higher risk of mortality and a more than 1,000-fold higher risk of progression to ESRD (compared with patients with estimated GFR >60 mL/min/1.73 m2 and ACR <30 mg/g; P < 0.001 for both outcomes). Conclusions: In this large cohort of diabetic KEEP participants with more than 170,000 person-years of follow-up, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction.
AB - Introduction: Chronic kidney disease may complicate diabetes, often manifesting with reduced glomerular filtration rate (GFR), albuminuria, or both. Although greater albuminuria and lower estimated GFR both predict adverse prognosis, whether a synergistic prognostic interaction occurs in patients with diabetes has not been defined in a large national cohort study. Methods: We used 2000-2011 data from the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) for 42,761 participants with diabetes. Kaplan-Meier survival analysis and multivariable Cox regression were used to ascertain the association of estimated GFR, albumin-creatinine ratio (ACR), and their interaction on all-cause mortality and progression to end-stage renal disease (ESRD) at a median 4 years of follow-up. Results: Of 42,761 participants with diabetes, 8,618 (20.2%) had estimated GFR <60 mL/min/1.73 m2, 7,715 (18.0%) had ACR >30 mg/g, and 2,641 (6.2%) had both. The unadjusted incidence (per 1,000 person-years) of all-cause mortality increased from 3.1 (95% CI, 2.4-3.8) in participants with estimated GFR ≥105 mL/min/1.73 m2 and no albuminuria to 73.7 (95% CI, 54.9-92.5) in participants with estimated GFR <30 mL/min/1.73 m2 and macroalbuminuria (P < 0.001). Progression to ESRD likewise increased from 0.2 (95% CI, 0-0.4) to 220.4 (95% CI, 177.2-263.6) per 1,000 person-years (P < 0.001). After adjustment for confounders, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction (P for interaction < 0.001); estimated GFR <30 mL/min/1.73 m2 and macroalbuminuria together were associated with a 5-fold higher risk of mortality and a more than 1,000-fold higher risk of progression to ESRD (compared with patients with estimated GFR >60 mL/min/1.73 m2 and ACR <30 mg/g; P < 0.001 for both outcomes). Conclusions: In this large cohort of diabetic KEEP participants with more than 170,000 person-years of follow-up, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction.
KW - Albuminuria
KW - chronic kidney disease
KW - diabetes mellitus
KW - end-stage renal disease
KW - glomerular filtration rate
KW - mortality
KW - nonalbuminuric chronic kidney disease
UR - http://www.scopus.com/inward/record.url?scp=84875152321&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2013.01.005
DO - 10.1053/j.ajkd.2013.01.005
M3 - Article
C2 - 23507266
AN - SCOPUS:84875152321
SN - 0272-6386
VL - 61
SP - S12-S23
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 4 SUPPL.2
ER -